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ABSTRACT
Purpose: To analyze the correlation between p53 and bcl-2 expression and colorectal adenocarcinoma staging and prognosis.
Methods: This was a retrospective series of 125 colorectal adenocarcinoma patients (67 women and 58 men; ages 30-87
years) who underwent surgery with curative intent. The mean follow-up was 28.5 months (range: 2-96 months). TNM
staging, tumor recurrence, survival and cancer-related mortality were analyzed. Immunoreactivity was evaluated using
DO7 (Dako) for p53 and K492 (Dako) for bcl-2. Tumors with accumulation of staining for cytoplasmic bcl-2 or nuclear p53
in more than 10% of cells were considered positive. Statistical analysis utilized Pearson chi-squared, log-rank and Wilcoxon
tests, and Kaplan-Meier survival estimation (significance level: p<0.05). Results: p53+ was found in 11.8% (14/118), bcl-2+
in 50% (58/116) and associated p53+/bcl-2+ in 6.4% (7/109) of the tumors. There was no significant correlation between
expression of these biomarkers and TNM I, II, III and IV staging (p=0.385 for p53; p=0.461 for bcl-2). For tumor recurrence,
p53+ was found in 9.5% (2/21), bcl-2+ in 50% (11/22), and associated p53+/bcl-2+ in 5.2% (1/19) of the tumors (p=0.714,
p=1.000 and p=0.960, respectively). For survival analysis, p53+: 57 months (45.0-68.0), bcl-2+: 78 (37.0-89.0), and p53+/bcl-
2+: 62 (56.0-68.0) (p=0.319). For cancer-related mortality, p53+: 8.3% (3/36), bcl-2+: 47.2% (17/36), and p53+/bcl-2+: 5.9% (2/
36) of the patients (p=0.432, p=0.688 and p=0.907, respectively). Conclusion: No correlation was found between tumor
expression of p53 and bcl-2 and the TNM staging, recurrence, survival and cancer-related mortality in colorectal
adenocarcinoma.
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RESUMO
Objetivo: Analisar a correlação entre a expressão da p53 e do bcl-2 com o estadiamento e prognóstico do adenocarcinoma
colorretal. Métodos: Foi realizado o estudo de uma série retrospectiva de 125 doentes com adenocarcinoma colorretal (67
mulheres e 58 homens; 30 a 87 anos de idade),  que se submeteram ao tratamento cirúrgico com intenção curativa. O tempo
médio de seguimento foi de 28,5 meses (variação de 2 a 96 meses). O estadiamento TNM, a recidiva tumoral, a sobrevida
e a mortalidade relacionada com o câncer foram analisados. A reação imunohistoquímica utilizada foi o DO& (Dako) para
o p53 e o K492 (Dako) para o bcl-2. Tumores com intensidade de coloração citoplásmica para o bcl-2 e nuclear para o p53,
acima de 10% de células foram considerados positivos. A análise estatística utilizada foi o teste qui-quadrado de Pearson,
log-rank, Wilcoxon e estimativa de sobrevida de Kaplan-Meier (nível de significância : p<0,05). Resultados: p53+ foi
encontrado em 11.8% (14/118), bcl-2+ em 50% (58/116) e associados p53+/bcl-2+ em 6.4% (7/109) dos tumores. Não foi
encontrado correlação significante entre a expressão tumoral destes marcadores e o estadiamento TNM I, II, III e IV
(p=0.385 para a p53; p=0.461 para o bcl-2). Na recidiva tumoral, p53+ foi encontrado em 9.5% (2/21), bcl-2+ em 50% (11/22),
e p53+/bcl-2+ associados em 5.2% (1/19) dos tumores (p=0.714, p=1.000 e p=0.960, respectivamente). Na análise de
sobrevida, p53+: 57 meses (45.0-68.0), bcl-2+: 78 (37.0-89.0), e p53+/bcl-2+: 62 (56.0-68.0) (p=0.319). Para mortalidade
relacionada com câncer, p53+: 8.3% (3/36), bcl-2+: 47.2% (17/36), e p53+/bcl-2+: 5.9% (2/36) dos pacientes (p=0.432,
p=0.688 and p=0.907, respectivamente). Conclusão: Nenhuma correlação significante foi encontrada entre a expressão
tumoral da p53 e do bcl-2 com o estadiamento TNM, recidiva, sobrevida e mortalidade relacionada com câncer.
Descritores: Neoplasias Colorretais. Marcadores Biológicos de Tumor. Estadiamento de Neoplasias. Prognóstico.
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Introduction
Colorectal cancer is a frequent cause of morbidity and
mortality and its prognosis is mainly based upon
histopathological staging. However, different clinical
outcomes are seen within each pathological stage. Thus,
the need for identifying better prognostic markers is easily
recognized. The search for new prognostic parameters is a
widely prevalent activity undertaken by pathologists and
indeed, for many, it seems to represent a form of Holy Grail1.
Despite great progress in the knowledge of the molecular
mechanism of cancer development and tumor progression,
very few biomarkers have been identified as independent
prognostic factors and none of them is used in ‘routine’
practice. A number of studies have shown that, for colorectal
adenocarcinoma, a biological profile based on combined
evaluation of these biomarkers may be useful for identifying
high-risk patients for enrollment in adjuvant treatment2,3,4.
In general, the currently available data on the correlation
between biomarkers and prognosis for colorectal cancer
are very often controversial. Carcinogenesis and even the
progression of the tumor seem to depend upon a controlled
balance between cell proliferation and cell death in the
normal colorectal mucosa. Two of the oncogenes implicated
in this process are p53 and bcl-2, which seem to play a very
important role in apoptosis. Mutation in the p53 gene gives
rise to an abnormal protein that accumulates in the nucleus,
thus allowing its detection by immunohistochemistry6. This
mutation leads to a reduction in the capacity to undergo
apoptotic cell death, and it could be an important step in
the development of neoplasia. Over the last ten years, a
very interesting field of study has emerged as a result of
investigations into the hypothesis that the p53 tumor
suppressor gene might show prognostic correlation with
cancer. Thus, a plethora of information has been provided,
but mostly without clinical significance. In spite of extensive
study of bcl-2 regarding hematopoietic malignancies,
relatively few data are available on it in relation to epithelium-
derived tumors3. bcl-2 is an intracellular membrane protein
that is capable of inhibiting apoptosis. Some studies have
shown that bcl-2 protein prolongs cell survival by blocking
programmed cell deaths. Controversial results have been
reported regarding the importance of bcl-2   as a prognostic
factor in colorectal cancer5,7,8,9,10. Both the tumor suppressor
gene p53 and the bcl-2 protein take part in the biological
cycle cell, and alterations to these genes are probably related
to oncogenesis and evolution of the disease. In the present
study we evaluated the potential prognostic correlation of
these biomarkers, separately and in association, and also
their relationship with pathological stages.
Methods
A retrospective series of 125 consecutive colorectal
adenocarcinoma patients admitted from December 1993 to
March 2000 was collected from the files of Hospital Sao
Paulo, Federal University of São Paulo – Escola Paulista de
Medicina (UNIFESP-EPM). The series consisted of 67
women and 58 men with ages ranging from 30 to 87 years.
The mean follow-up was 28.5 months, ranging from 2 months
to 96 months.
All patients underwent surgery with curative intent.
The outcome was curative for 98 patients (78,4%), while it
was palliative for the remaining 27 (21,6%). The resection
was regarded as curative when the surgeon was able to
identify that no tumor was left behind and when there was
histopathological evidence of a clear surgical margin on
the surgical specimen. No patient underwent neoadjuvant
therapy. The was focused specifically on local and distant
recurrence, survival analysis and cancer-related mortality.
Tumor tissues were pathologically staged according to the
TNM classification, as follows: 21 patients (16,8%) were
classified as stage I, 41 (32,8%) as stage II, 28 (22,4%) as
stage III, and 35 (28%) as stage IV.
TABLE 1 - Colorectal adenocarcinoma patients
characteristics.
n = 125
Sex ratio (M:F) 58/67
Mean age (years) 63,4 (30/87)
Tumour site
Right colon 33(26,4%)
Left colon 27(21,6%)
Rectum 65(52,0%)
Residual disease status
None 98(78,4%)
Local 27(21,6%)
Mean follow-up time(months) 28,5(2/96)
Cancer-related mortality 22(22,4%)
Recurrence
Local 24(24,4%)
Metastatic 0
TNM Stage
I 21(16,8%)
II 41(32,8%)
III 28(22,4%)
IV 35(28,0%)
Formalin-fixed and paraffin-embedded tissue samples
of colorectal cancer were cut into 4-mm sections and dried
overnight at 60°C. Representative sections were stained
using hematoxylin-eosin prior to immunostaining, to ensure
that the slides showed tumor tissue as the regions of interest.
All the slides were examined and scored independently by
three investigators in blinded fashion, without knowledge
of the clinical and histopathological data. Any initial
divergences in the reviewers’ results were followed by
reevaluation in order to reach consensus. Immunoreactivity
for the p53 protein was detected by using monoclonal
antibody DO7 (Dako, Denmark). Tumors were considered
to be positive for p53 when more than 10% of the cells were
stained, excluding areas with faintly stained cells, or positive
cells located at the margins of the section or in areas with
poor morphology. bcl-2 expression was analyzed by using
the K492 kit (Dako, Denmark). Tumors were considered to
be positive for bcl-2 when more than 10% of the cells
accumulated cytoplasmic bcl-2 staining. Tumor cells were
only considered positive for bcl-2 when the cytoplasmic
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immunoreaction was strong and homogeneous. In the
statistical analysis, the survival curve was estimated by the
Kaplan-Meier product-limit method. The log-rank test and
chi-squared tests were used to assess differences between
subgroups. Cox univariate modeling was used to estimate
the relative risk and the confidence limits for each variable.
A multivariate Cox proportional hazard model was also
produced using stepwise regression. The Wilcoxon test
(Breslow version) was used to analyze the degree of
significance between variables. Statistical significance was
assessed at the 5% level (p<0.05).
Results
The protein p53+ was found in 11.8% (14/118) of the
tumors, bcl-2+ in 50% (58/116), and a combination of p53+
and bcl-2+ in 6.4% (7/109). No significant correlation was
found between biomarker expression and TNM I, II, III and
IV staging (p=0.385 for p53+; p=0.461 for bcl-2+; and p=0.937
for the association of p53+ and bcl-2+). The tumor recurrence
rate was not associated with p53+ (p=0.714), bcl-2+
(p=1.000), and the association of p53+ and bcl-2+ (p=0.960).
Survival analysis for p53+ showed a mean of 57 months
(range: 45.0 – 68.0); for bcl-2+ it was 78 months (37.0 – 89.0);
and for the association of p53+ and bcl-2+, it was 62 months
(56.0 – 68.0) (p=0.319). Cancer-related mortality occurred in
p53+ tumors in 83% of the patients (3/36) (p=0.432); in bcl-
2+ tumors in 47.2% of the patients (17/36) (p=0.688); and in
the association of p53+ and bcl-2+ tumors in 5.9% of the
patients (2/36) (p=0.907).
TABLE 2 - Tumour expression of p53, bcl-2 and associated
p53/bcl-2.
p53 bcl-2 p53 and bcl-2
n (%) n.(%) n.(%)
positive 14(11) 58(50) 11(14,6)
negative 104(89) 58(50) 64(85,4)
Total 108(100) 116(100) 75(100)
TABLE 3 - Tumour recurrence and expression of p53, bcl-
2 and associated p53/bcl-2.
p53 bcl-2 p53 and bcl-2
n (%) n.(%) n.(%)
positive 2 (9,5) 11 (50) 1 (5,2)
negative 19 (90,5) 11 (50) 10 (52,7)
Total 21 (100) 22 (100) 19 (100)
p53 mean Confidence Interval
Positive 57,0 45,0 ; 68,0
Negative 75,0 66,0 ; 84,0
Wilcoxon Test(Breslow version): p = 0,7258
FIGURE 1 - Kaplan-Meier curves for cumulative survival in
118 patients with colorectal adenocarcinoma
according to p53 status.
bcl-2-2 mean Confidence interval
positive 78,0 37,0 ; 89,0
negative 73,0 61,0 ; 85,0
              log-rank test: p = 0,471
FIGURE 2 - Kaplan-Meier curves for cumulative survival in
116 patients with colorectal adenocarcinoma
according to bcl-2 status.
Lustosa SAS et al
356 - Acta Cirúrgica Brasileira - Vol 20 (5) 2005
Discussion
The limitations of histopathological parameters for
identifying subgroups among colorectal cancer patients that
may benefit from adjuvant therapy are obvious, considering
TABLE 4 - p53 tumour expression and TNM staging.
p 53 TNM I TNM II TNM III TNM IV
n (%) n (%) n (%) n (%)
positive 3 (9,0) 4 (19,0) 5 (16,7) 2 (5,8)
negative 30 (91,0) 17 (81,0) 25 (83,3) 32 (94,2)
total 33 (100,0) 21 (100,0) 30 (100,0) 34 (100,0)
p = 0,385
TABLE 5 - bcl-2 tumour expression and TNM staging.
bcl-2 TNM I TNM II TNM III TNM IV
n (%) n (%) n (%) n (%)
positive 14 (50,0) 9 (39,0) 18 (60,0) 16 (45,7)
negative 14 (50,0) 14 (61,0) 12 (40,0) 19 (54,3)
total 28 (100,0) 23 (100,0) 30 (100,0) 35 (100,0)
p = 0,476
TABLE 6 - Associated p53 and bcl-2 tumour expression
with TNM staging.
p 53 and bcl-2 TNM I TNM II TNM III TNM IV
n (%) n (%) n (%) n (%)
positive 1 (8,4) 1 (6,6) 2 (16,7) 2 (11,8)
negative 11 (91,6) 14 (93,4) 10 (83,3) 15 (88,2)
total 12 (100,0) 15 (100,0) 12 (100,0) 17 (100,0)
p = 0,937
FIGURE 3 - Kaplan-Meier curves for cumulative survival in
11 patients with colorectal adenocarcinoma
according to associated p53 and bcl-2 status.
p53 e bcl-2 mean Confidence interval
positive 62,0 56,0 ; 68,0
           log-rank test: p = 0,454
that different outcomes are frequently seen in each
pathological stage. Improvement in colorectal cancer
therapy can only be achieved if new tumor markers with
significant prognostic potential can be identified. There has
been an intensive search for such markers, but none of
them can be considered to be independent prognostic
variables. The histopathological parameter that is most used,
the presence of lymph node metastasis, is an example of
this11. Over the last ten years, a large volume of scientific
information has been made available through a huge number
of studies. However, the results from these are mostly of no
clinical relevance. These studies have mainly focused on
biological markers, which have been recognized as key
factors in the understanding of the process of oncogenesis.
Thus, in spite of the recent progress in defining the molecular
mechanism for cancer development, only few individual
biomarkers providing prognostic information have been
identified12. Although Fearon & Vogelstein put forward a
good model for the temporal sequence of the genetic
alterations occurring in colorectal tumorigenesis, so far it is
not clear whether positive p53 immunoreactivity can identify
a subset of tumors with distinct biological behaviour13.
It has been reported that the great variation in study
methodologies is responsible for the heterogeneity of the
results. The patient selection, specimen processing,
immunohistochemical techniques, data interpretation and
statistical analysis have been so variable that it makes the
interpretation of the published literature at best difficult1.
In our study we used formalin-fixed paraffin-embedded
tissues, and the sections were microwave processed before
being incubated with the primary antibody. This type of
treatment has been reported to be an excellent antigen
retrieval method for p533,14,15. In immunohistochemical
studies, a threshold must be set for the amount of cells
staining, in order to distinguish positive biological samples
from negative ones. In our study, the level at which we
considered the marker expression to be positive was set on
the basis of the majority of cutoff points used in the recent
literature. If the threshold is chosen on the basis of the best
separation of clinical outcomes, it is obvious that the validity
of the study is questionable1. On the other hand as, in our
study, three examiners analyzed the sections, in a blinded
manner and without knowledge of the clinical and
pathological data, the possibility of measurement bias may
have been decreased. Based on the results from the present
study, we  are able to say that  the p53 and bcl-2 proteins
seem not to have prognostic potential for patients with
colorectal adenocarcinoma. In fact, Dowell and Hall1 showed
that p53 in particular is only a weak prognostic factor that
cannot alone identify a group with such a low risk of
recurrence that treatment would not be indicated. According
to these authors, while p53 is of undisputed importance in
our understanding of oncogenesis and neoplasia, it would
seem that the Holy Grail has not yet been found. We could
not agree more1. There seems to be a very close correlation
between the sample size in a study and the probability that
p53 is regarded as an independent prognostic variable.
Thus, we may need large groups of patients in order to get
enough statistical power to demonstrate the significance
of this biomarker. This implies that p53 is only a relatively
weak prognostic factor1. A review of the literature by
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Tollenaar et al.5 led to the same conclusion. In the same
way, 46 studies that assessed the prognostic value of p53
status, which we obtained from a Medline search between
1995 and 2002, confirmed that there is a strong correlation
between the number of cases in the study and the possibility
that p53 could be a prognostic factor. A recent and
comprehensive review of tumor molecular markers and their
prognostic significance concluded that the relevant data
are contradictory and that, until further data become
available, histopathological parameters such as the T and
N categories are at present more meaningful17. Our results
using bcl-2 are in accordance with recent published
literature. Thus, we could not find any degree of significance
in any of the prognostic parameters studied. Likewise, we
were unable to correlate the histopathological findings and
TNM categories with bcl-2 expression, on the basis of the
proposition that the bcl-2 protein alterations may occur very
early in oncogenesis18. The combined evaluation of p53
and bcl-2 expression in the tumor was of no value for
reaching prognostic significance. We find that there is no
reason at all to share in the optimism expressed in the
literature regarding the combination of these two markers
for making colorectal cancer prognoses. The rationale
behind these markers, based on their logical participation
in the apoptosis process, does not justify the intensive
research into their prognostic significance.
Conclusion
On the basis of our findings we conclude that p53 and
bcl-2 probably have no potential to act as significant
parameters in colorectal cancer staging and prognosis.
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